Key result
Systemic inflammation and endothelial dysfunction drive HFpEF, highlighting the NO-sGC-cGMP pathway as a key therapeutic target.
Answers are grounded in this paper and cite their sources.
This review highlights a novel paradigm in HFPEF where systemic inflammation and endothelial dysfunction drive the disease, identifying the NO-sGC-cGMP pathway as a key therapeutic target.
Heart failure with preserved ejection fraction (HFPEF) is a global health problem of considerable socioeconomic burden. It is projected to worsen with the aging population worldwide. The lack of effective therapies underscores our incomplete understanding of this complex heterogeneous syndrome. A novel paradigm has recently emerged, in which central roles are ascribed to systemic inflammation and generalized endothelial dysfunction in the pathophysiology of HFPEF. In this review, we discuss the role of the endothelium in cardiovascular homeostasis and how deranged endothelial-related signaling pathways contribute to the development of HFPEF. We also review the novel therapies in various stages of research and development that target different components of this signaling pathway.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2015) conducted a review in Heart failure with preserved ejection fraction (HFPEF). Systemic inflammation and generalized endothelial dysfunction play central roles in the pathophysiology of heart failure with preserved ejection fraction, highlighting the NO-sGC-cGMP pathway as a key therapeutic target.
Synapse has enriched 10 related papers. Consider them for comparative context: